Compare · ORKA vs QCLS
ORKA vs QCLS
Side-by-side comparison of Oruka Therapeutics Inc. (ORKA) and Q/C Technologies Inc. (QCLS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ORKA and QCLS operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $4.89B, about 1071.2x QCLS ($4.6M).
- Both names hit the wire about 3 times in the past 4 weeks.
- ORKA has more recent analyst coverage (11 ratings vs 0 for QCLS).
- Company
- Oruka Therapeutics Inc.
- Q/C Technologies Inc.
- Price
- -
- -
- Market cap
- $4.89B
- $4.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 3
- 3
- Recent ratings
- 11
- 0
Latest ORKA
- SEC Form 4 filed by Oruka Therapeutics Inc.
- SEC Form 4 filed by Oruka Therapeutics Inc.
- Chief Executive Officer Klein Lawrence Otto exercised 25,000 shares at a strike of $7.80 and sold $2,090,593 worth of shares (25,000 units at $83.62) as part of a pre-agreed trading plan (SEC Form 4)
- Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
- Senior Vice President, Finance Agarwal Arjun sold $51,035 worth of shares (533 units at $95.75) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 14,219 units (SEC Form 4)
- General Counsel Quinlan Paul T exercised 10,000 shares at a strike of $7.80 and sold $936,417 worth of shares (10,000 units at $93.64) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $734,145 worth of shares (7,947 units at $92.38) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 31,771 units (SEC Form 4) (for tax liability)
- Senior Vice President, Finance Agarwal Arjun sold $926,010 worth of shares (10,019 units at $92.43) as part of a pre-agreed trading plan and exercised 9,459 shares at a strike of $15.88, decreasing direct ownership by 4% to 14,752 units (SEC Form 4) (for tax liability)
- Chief Executive Officer Klein Lawrence Otto sold $234,681 worth of shares (2,452 units at $95.71), decreasing direct ownership by 0.26% to 923,128 units (SEC Form 4) to cover withholding tax
- General Counsel Quinlan Paul T sold $99,443 worth of shares (1,039 units at $95.71), decreasing direct ownership by 3% to 29,995 units (SEC Form 4) to cover withholding tax
Latest QCLS
- Executive Chairman Silverman Joshua was granted 94,010 shares, increasing direct ownership by 80% to 210,845 units (SEC Form 4)
- Amendment: Executive Chairman Silverman Joshua was granted 16,806 shares, increasing direct ownership by 17% to 116,835 units (SEC Form 4)
- Q/C Technologies Announces Research Collaboration with Sandia National Laboratories, a $5 Billion U.S. Department of Energy Lab
- SEC Form 3 filed by new insider Ehrlichman Yossef
- Q/C Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Q/C Technologies Names Yossef Ehrlichman Chief Technology Officer to Lead Optical Processor Development
- Q/C Technologies Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits
- SEC Form 3 filed by new insider Fagan Charles Todd
- SEC Form 10-Q filed by Q/C Technologies Inc.
- Q/C Technologies Appoints Veteran Silicon Photonics Engineer Yossef Ehrlichman as Founding Manager, Photonic Integrated Circuit (PIC) Development